Circulating tumor cells before and during follow-up after breast cancer surgery.

Guus van Dalum, Gert Jan Stam, Arjan G.J. Tibbe, Bas Franken, Walter J.B. Mastboom, I. Vermes, Marco R. De Groot, Leonardus Wendelinus Mathias Marie Terstappen

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Scopus)

Abstract

The presence of circulating tumor cells (CTC) is an independent prognostic factor for progression-free and overall survival for patients with metastatic and newly diagnosed breast cancer. The present study was undertaken to explore whether the presence of CTC before and during follow-up after surgery is associated with recurrence free survival (RFS) and overall survival (OS). In a prospective single center study, CTC were enumerated with the CellSearch system in 30 ml of peripheral blood of 403 stage I-III patients before undergoing surgery for breast cancer (A) and if available 1 week after surgery (B), after adjuvant chemo- and/or radiotherapy or before start of long-term hormonal therapy (C), one (D), two (E) and three (F) years after surgery. Patients were stratified into unfavorable (CTC ≥1) and favorable (CTC=0) prognostic groups. >1 CTC in 30 ml blood was detected in 75/403 (19%) at A, 66/367 (18%) at B, 40/263 (15%) at C, 30/235 (12%) at D, 18/144 (11%) at E and 11/83 (13%) at F. RFS and OS was significantly lower for unfavorable CTC as compared to favorable CTC before surgery (p=0.022 and p=0.006), after adjuvant therapy (p<0.001 and p=0.018) and one (p=0.006 and p=0.013) and two (p<0.001 and p=0.045) years after surgery, but not 1 week post-surgery. The presence of CTC in blood drawn pre and one and two years after surgery, but not post-surgery is associated with shorter RFS and OS for stage I-III breast cancer
Original languageEnglish
Pages (from-to)407-413
JournalInternational journal of oncology
Volume46
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Circulating Neoplastic Cells
Breast Neoplasms
Survival
Recurrence
Disease-Free Survival
Radiotherapy

Keywords

  • IR-95620
  • METIS-307080

Cite this

van Dalum, Guus ; Stam, Gert Jan ; Tibbe, Arjan G.J. ; Franken, Bas ; Mastboom, Walter J.B. ; Vermes, I. ; De Groot, Marco R. ; Terstappen, Leonardus Wendelinus Mathias Marie. / Circulating tumor cells before and during follow-up after breast cancer surgery. In: International journal of oncology. 2015 ; Vol. 46, No. 1. pp. 407-413.
@article{c4a7c689289f46beb1f192c37351903c,
title = "Circulating tumor cells before and during follow-up after breast cancer surgery.",
abstract = "The presence of circulating tumor cells (CTC) is an independent prognostic factor for progression-free and overall survival for patients with metastatic and newly diagnosed breast cancer. The present study was undertaken to explore whether the presence of CTC before and during follow-up after surgery is associated with recurrence free survival (RFS) and overall survival (OS). In a prospective single center study, CTC were enumerated with the CellSearch system in 30 ml of peripheral blood of 403 stage I-III patients before undergoing surgery for breast cancer (A) and if available 1 week after surgery (B), after adjuvant chemo- and/or radiotherapy or before start of long-term hormonal therapy (C), one (D), two (E) and three (F) years after surgery. Patients were stratified into unfavorable (CTC ≥1) and favorable (CTC=0) prognostic groups. >1 CTC in 30 ml blood was detected in 75/403 (19{\%}) at A, 66/367 (18{\%}) at B, 40/263 (15{\%}) at C, 30/235 (12{\%}) at D, 18/144 (11{\%}) at E and 11/83 (13{\%}) at F. RFS and OS was significantly lower for unfavorable CTC as compared to favorable CTC before surgery (p=0.022 and p=0.006), after adjuvant therapy (p<0.001 and p=0.018) and one (p=0.006 and p=0.013) and two (p<0.001 and p=0.045) years after surgery, but not 1 week post-surgery. The presence of CTC in blood drawn pre and one and two years after surgery, but not post-surgery is associated with shorter RFS and OS for stage I-III breast cancer",
keywords = "IR-95620, METIS-307080",
author = "{van Dalum}, Guus and Stam, {Gert Jan} and Tibbe, {Arjan G.J.} and Bas Franken and Mastboom, {Walter J.B.} and I. Vermes and {De Groot}, {Marco R.} and Terstappen, {Leonardus Wendelinus Mathias Marie}",
year = "2015",
doi = "10.3892/ijo.2014.2694",
language = "English",
volume = "46",
pages = "407--413",
journal = "International journal of oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

Circulating tumor cells before and during follow-up after breast cancer surgery. / van Dalum, Guus; Stam, Gert Jan; Tibbe, Arjan G.J.; Franken, Bas; Mastboom, Walter J.B.; Vermes, I.; De Groot, Marco R.; Terstappen, Leonardus Wendelinus Mathias Marie.

In: International journal of oncology, Vol. 46, No. 1, 2015, p. 407-413.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Circulating tumor cells before and during follow-up after breast cancer surgery.

AU - van Dalum, Guus

AU - Stam, Gert Jan

AU - Tibbe, Arjan G.J.

AU - Franken, Bas

AU - Mastboom, Walter J.B.

AU - Vermes, I.

AU - De Groot, Marco R.

AU - Terstappen, Leonardus Wendelinus Mathias Marie

PY - 2015

Y1 - 2015

N2 - The presence of circulating tumor cells (CTC) is an independent prognostic factor for progression-free and overall survival for patients with metastatic and newly diagnosed breast cancer. The present study was undertaken to explore whether the presence of CTC before and during follow-up after surgery is associated with recurrence free survival (RFS) and overall survival (OS). In a prospective single center study, CTC were enumerated with the CellSearch system in 30 ml of peripheral blood of 403 stage I-III patients before undergoing surgery for breast cancer (A) and if available 1 week after surgery (B), after adjuvant chemo- and/or radiotherapy or before start of long-term hormonal therapy (C), one (D), two (E) and three (F) years after surgery. Patients were stratified into unfavorable (CTC ≥1) and favorable (CTC=0) prognostic groups. >1 CTC in 30 ml blood was detected in 75/403 (19%) at A, 66/367 (18%) at B, 40/263 (15%) at C, 30/235 (12%) at D, 18/144 (11%) at E and 11/83 (13%) at F. RFS and OS was significantly lower for unfavorable CTC as compared to favorable CTC before surgery (p=0.022 and p=0.006), after adjuvant therapy (p<0.001 and p=0.018) and one (p=0.006 and p=0.013) and two (p<0.001 and p=0.045) years after surgery, but not 1 week post-surgery. The presence of CTC in blood drawn pre and one and two years after surgery, but not post-surgery is associated with shorter RFS and OS for stage I-III breast cancer

AB - The presence of circulating tumor cells (CTC) is an independent prognostic factor for progression-free and overall survival for patients with metastatic and newly diagnosed breast cancer. The present study was undertaken to explore whether the presence of CTC before and during follow-up after surgery is associated with recurrence free survival (RFS) and overall survival (OS). In a prospective single center study, CTC were enumerated with the CellSearch system in 30 ml of peripheral blood of 403 stage I-III patients before undergoing surgery for breast cancer (A) and if available 1 week after surgery (B), after adjuvant chemo- and/or radiotherapy or before start of long-term hormonal therapy (C), one (D), two (E) and three (F) years after surgery. Patients were stratified into unfavorable (CTC ≥1) and favorable (CTC=0) prognostic groups. >1 CTC in 30 ml blood was detected in 75/403 (19%) at A, 66/367 (18%) at B, 40/263 (15%) at C, 30/235 (12%) at D, 18/144 (11%) at E and 11/83 (13%) at F. RFS and OS was significantly lower for unfavorable CTC as compared to favorable CTC before surgery (p=0.022 and p=0.006), after adjuvant therapy (p<0.001 and p=0.018) and one (p=0.006 and p=0.013) and two (p<0.001 and p=0.045) years after surgery, but not 1 week post-surgery. The presence of CTC in blood drawn pre and one and two years after surgery, but not post-surgery is associated with shorter RFS and OS for stage I-III breast cancer

KW - IR-95620

KW - METIS-307080

U2 - 10.3892/ijo.2014.2694

DO - 10.3892/ijo.2014.2694

M3 - Article

VL - 46

SP - 407

EP - 413

JO - International journal of oncology

JF - International journal of oncology

SN - 1019-6439

IS - 1

ER -